For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.

The FDA spent more than 15 years crafting the guidelines, which are designed to do away with industry practices that downplay ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

A new study published in JAMA Psychiatry linked GLP-1 receptor agonists like Ozempic with a lower risk of alcohol-related ...

The study adds that “Similar reductions were seen across obesity status, gender, and age groups,” although “further clinical ...

WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Most people regain some of the weight they lost after stopping semaglutide. However, physical activity and a balanced diet may help you keep some weight off. Share on Pinterest LeoPatrizi/Getty ...

Researchers at Helix found that an integrated polygenic risk score with co-morbid factors such as the presence of type 2 diabetes and hypertension could predict the 12 month weight loss response to ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths ...

Semaglutide linked to significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs. HealthDay News — For patients with type 2 diabetes mellitus ...